---
title: "Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293617770.md"
description: "China's NMPA approved Hengrui Pharma's camrelizumab and famitinib combination as a first-line treatment for PD-L1-positive recurrent or metastatic cervical cancer. This approval upgrades the regimen from second-line to first-line use, based on Phase III trial results showing a median overall survival of 35.8 months compared to 23.6 months with chemotherapy."
datetime: "2026-07-23T12:32:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293617770.md)
  - [en](https://longbridge.com/en/news/293617770.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293617770.md)
---

# Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment

-   China’s NMPA cleared camrelizumab injection with famitinib malate for first-line recurrent or metastatic cervical cancer in PD-L1-positive patients. \* The decision upgrades the regimen from second-line to first-line use in advanced cervical cancer. \* Approval follows a phase III trial showing median OS of 35.8 months vs 23.6 months on chemotherapy in the PD-L1-positive subgroup (HR 0.634). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12254653), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Jiangsu Hengrui files HKEX next-day disclosure return reporting share repurchase at RMB 52.96](https://longbridge.com/en/news/294665198.md)
- [Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use](https://longbridge.com/en/news/293620453.md)
- [Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin Analog](https://longbridge.com/en/news/294227320.md)
- [Alphamab Oncology says China CDE clears JSKN033 Phase 3 trial in recurrent or metastatic cervical cancer](https://longbridge.com/en/news/294703091.md)
- [Metis TechBio to Deploy AI Formulation Platform at Hengrui Pharmaceuticals](https://longbridge.com/en/news/294641344.md)